News | January 28, 2024
Novartis India posts Q3 FY24 PAT at Rs. 26.57 Cr
Novartis India has reported total income of Rs. 106.50 crores during the period ended December 31, 2023
Novartis India has reported total income of Rs. 106.50 crores during the period ended December 31, 2023
Gabapentin is indicated for the management of Postherpetic Neuraligia
The Pregabalin capsules has a market size of ~US$248 mn per IQVIA
For 9 months period ended December 2023, the company’s PAT up 16% to Rs 330 crores (before exceptional items)
Denifanstat achieved statistically significant results on primary and multiple secondary endpoints in a 52-week clinical trial
Glenmark Life Sciences has reported total income of Rs. 574.49 crores during the period ended December 31, 2023
The receipt of this permission paves way for the launch of Andexanet alfa powder for solution for infusion 200 mg (Andexxa) in India
GMP certification helps enable biotechnology customers to accelerate accessibility of new RNA-based therapies for patients
Produodopa is the first-and-only subcutaneous 24-hour infusion of levodopa-based therapy for the treatment of severe motor fluctuations
Synthon will be responsible for obtaining US regulatory approval for Palbociclib Tablets
Subscribe To Our Newsletter & Stay Updated
